

The Second International Conference on Deficiency of ADA2

Agenda

FRIDAY, NOVEMBER 9, 2018

7:00 to 7:50	Registration and Continental Breakfast
8:00 to 8:20	Welcome/Introductions/Agenda Overview <i>Chip Chambers, M.D. - Founder & President DADA2 Foundation</i> <i>Dan Kastner, M.D., Ph.D. - Scientific Director NHGRI, National Institutes of Health</i>

SESSION 1: NEW CLINICAL MANIFESTATIONS OF DADA2

8:20 to 8:35	How Much Agreement is There on the Diagnosis & Treatment of DADA2 – A World Wide Survey <i>Taryn Youngstein, M.D. – Imperial College Healthcare NHS Trust, London, England</i>
8:35 to 8:55	Deficiency of ADA2 a Perspective from ADA1 Deficiency <i>Mike Hershfield, M.D. – Duke University School of Medicine</i>
8:55 to 9:10	Deficiency of ADA2 a Year-in-Review <i>Ivona Aksentjevich, M.D. – NHGRI, NIH, Co-Chair 2nd International DADA2 Conference</i>
9:10 to 9:25	What is Unique about DADA2 Patients of European Descent? <i>Marco Gattorno, M.D. - Giannina Gaslini Institute, Genoa, Italy</i>
9:25 to 9:35	What is Unique about DADA2 Patients of Middle Eastern and Eastern Mediterranean Descent? <i>Seza Ozen, M.D. – Hacettepe University of Medicine, Ankara, Turkey</i>
9:35 to 9:50	Diamond-Blackfan Anemia Phenotype Caused by Deficiency of Adenosine Deaminase 2 <i>Marcin Wlodarski, M.D., Ph.D. – St. Jude Children’s Research Hospital</i>
9:50 to 10:00	ADA2 Deficiency: Clonal Lymphoproliferation in a Subset of Patients <i>Janna Saarela, M.D., Ph.D. - Institute for Molecular Medicine, Helsinki, Finland</i>
10:00 to 10:20	COFFEE BREAK and NETWORKING
10:20 to 10:30	Is Deficiency of Adenosine Deaminase 2 Associated with Lymphoma? <i>Fahad Alabbas, M.D., Prince Sultan Military Medical City, Riyadh, Saudi Arabia</i>

SESSION 1: NEW CLINICAL MANIFESTATIONS OF DADA2

10:30 to 10:40	ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman's Disease Erika Van Nieuwenhove, M.D. - University Hospitals Gasthuisberg, Leuven, Belgium
10:40 to 10:50	DADA2 Presenting as Bone Marrow Failure in Adulthood & Response to TNF-Inhibition Thomas Michniacki, M.D. – University of Michigan Medical School
10:50 to 11:00	Early Diagnosis of an Infant with DADA2 – Japanese Cohort Kazushi Izawa, M.D., Ph.D. – Kyoto University Hospital, Kyoto, Japan
11:00 to 11:15	Can Carriers Express the DADA2 Phenotype & Require Treatment? Pui Lee, M.D., Ph.D., - Harvard Medical School
11:15 to 12:15	Q & A WITH ALL PRESENTERS ON STAGE
12:15 to 12:45	PICK UP LUNCH

SESSION 2: NEW INSIGHTS INTO THE PATHOPHYSIOLOGY OF DADA2

12:45 to 12:55	Variable Clinical Phenotypes and Relation of Interferon Signature with Disease Activity in DADA2 Antonella Insalaco, M.D. - I.R.C.C.S. Ospedale Pediatrico Bambino Gesù, Rome, Italy
12:55 to 1:10	Disrupted N-Linked Glycosylation as a Disease Mechanism in Deficiency of ADA2 Pui Lee, M.D., Ph.D. - Harvard Medical School
1:10 to 1:25	Vascular Endothelium & the ADA2 Molecule Rekha Dhanwani, Ph.D. - La Jolla Institute of Allergy and Immunology
1:25 to 1:45	ADA2 is a Lysosomal Nuclease Involved in Nucleic Acid Sensing of Myeloid Cells Ole Kristian Greiner-Tollersrud, Ph.D. - Institute of Medical Biology University of Tromsø, Norway Michele Proeitti, Ph.D. – Center for Chronic Immunodeficiency, Freiburg, Germany
1:45 to 2:00	Deficiency in Human Adenosine Deaminase 2 Alters Cellular Responses to Extracellular Adenosine Andrey Zavialov, Ph.D. – Guangzhou Institute of Pediatrics, Guangzhou (Canton), China
2:00 to 2:15	ADA2 Deficiency Triggers Adenosine - Mediated NET Formation and TNF Production in Patients with DADA2 Peter Grayson, M.D. – NIAMS, NIH
2:15 to 2:30	Vascular Inflammation in DADA2 Patients: Pre and Post TNF-Inhibition Dan Yang, M.D., Ph.D. – NHLBI, NIH
2:30 to 2:45	Deficiency of Adenosine Deaminase 2 in Patients Diagnosed with PAN Oskar Schnappauf, Ph.D. – NHGRI, NIH
2:45 to 3:00	Expanded Spectrum of Peripheral Blood Findings and Bone Marrow Pathology in DADA2 Kathy Calvo, M.D., Ph.D., - Department of Laboratory Medicine - Hematopathology, NIH
3:00 to 3:50	Q & A WITH ALL PRESENTERS ON STAGE
3:50 to 4:10	COFFEE BREAK and NETWORKING

SESSION 3: TREATMENT OF DADA2

4:10 to 4:25	A Decision Tree for the Genetic Diagnosis of DADA2: A French Reference Centers Experience <i>Sophie Georgin-Lavialle, M.D., Ph.D. - Pierre and Marie Curie University, Paris, France</i>
4:25 to 4:40	Pre-Clinical Study on Gene Therapy for DADA2 – Great Ormond Street Hospital’s Experience <i>Despina Eleftheriou, MBBS, MRCPCH, Ph.D. - UCL Great Ormond St Institute of Child Health, London, England</i>
4:40 to 4:55	Pre-Clinical Study on Gene Therapy for DADA2 – San Raffaele Hospital’s Experience <i>Alessandra Mortellaro, Ph.D. - San Raffaele Telethon Institute for Gene Therapy, Milan, Italy</i>
4:55 to 5:15	Analysis on the Efficacy of Anti-TNF in the Treatment of Patients with DADA2 - The NIH Experience <i>Amanda Ombrello, M.D. – NHGRI, NIH</i>
5:15 to 5:30	Bone Marrow Transplant for DADA2 – Where are we now? <i>Isabelle Meyts, M.D., Ph.D. - University Hospitals Gasthuisberg, Leuven, Belgium</i>
5:30 to 6:00	Q & A WITH ALL PRESENTERS ON STAGE

SESSION 4: JOINT PHYSICIANS/SCIENTISTS & PATIENTS/FAMILIES

6:00 to 6:30	SUMMARY OF THE DAY <i>Dan Kastner, M.D., Ph.D. - Scientific Director NHGRI, National Institutes of Health</i>
6:30 to 7:30	JOINT RECEPTION FOR PHYSICIANS/SCIENTISTS & PATIENTS/FAMILIES

SATURDAY, NOVEMBER 10, 2018

7:30 to 8:00	Continental Breakfast	White Oak Foyer
8:00 to 8:30	Introduction to day # 2	White Oak A
8:30 to 12:00	Scientific Advisory Board	Forest Glen
8:30 to 12:00	Diagnosis & Screening DADA2 Collaborative Group	Oakley Room
8:30 to 12:00	Gene Therapy DADA2 Collaborative Group	Middlebrook Room
8:30 to 12:00	Hematopoietic Stem Cell Transplant	Timberlawn Room
8:30 to 12:00	Neurological Phenotype	Strathmore Hall Room
8:30 to 12:00	Pathophysiology	Linden Oak Room
8:30 to 12:00	Patient Reported Outcomes	Glen Echo Room
12:00	CONCLUSION OF THE DADA2 CONFERENCE	